GlassScriptPhysician profile
Gurprit Sekhon
NPI 1871541094
$16,214.55
in general payments reported to CMS, 2019-2025
55 companies · $2,772 in 2025
The $2,772 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,466 · 2020: $1,779 · 2021: $2,166 · 2022: $1,837 · 2023: $3,175 · 2024: $2,019 · 2025: $2,772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,735 · Education: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,734.85 |
| Education | $231.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,270.85 | 2019-2025 | Airsupra, Farxiga, Fasenra |
| Abbvie INC. | $1,737.91 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $1,014.02 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $1,007.28 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Lilly USA, LLC | $979.83 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $793.46 | 2019-2025 | Ofev, Jardiance, Synjardy |
| Otsuka America Pharmaceutical, INC. | $644.91 | 2021-2025 | Rexulti, Nuedexta |
| Pfizer INC. | $546.35 | 2019-2025 | |
| Novo Nordisk INC | $507.02 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $501.33 | 2021-2025 | |
| Amgen INC. | $490.83 | 2019-2025 | Repatha, Otezla, Evenity |
| Allergan, INC. | $418.65 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $390.00 | 2019-2024 | Spravato, Xarelto |
| Amarin Pharma, INC. | $304.50 | 2019-2021 | |
| Lundbeck LLC | $303.25 | 2021-2025 | Rexulti |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gurprit Sekhon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.